The
following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders
for the periods presented, because including them would have had an anti-dilutive effect:
SCHEDULE
OF ANTI-DILUTIVE EFFECT
| | |
December 31, 2024 | | |
December 31, 2023 | |
| Unvested common stock – restricted shares (Note 8) | |
| 62,706 | | |
| 1,640,505 | |
| Restricted stock options | |
| 709,992 | | |
| - | |
| Restricted stock units | |
| 2,486,403 | | |
| - | |
| Performance stock units | |
| 506,596 | | |
| - | |
| Public warrants | |
| 4,864,133 | | |
| - | |
| Private placement warrants | |
| 5,566,667 | | |
| - | |
| * |
|
The Sponsor Earnout Shares
(as defined in the Business Combination Agreement) were not included for purposes of calculating the number of diluted shares outstanding
as of December 31, 2024, as the Sponsor earnout shares remain contingently forfeitable, as the conditions have not been met |
|